Patent ID: 8293714

Claim:
A compound of the formula: R 1 -[VEGF-Peptide]-R 2 wherein [VEGF-Peptide] is a peptide having the sequence: V 1 -E 2 -P 3 —N 4 —C 5 -D 6 -I 7 —H 8 —V 9 -M 10 -W 11 —V 12 —W 13 —X 14 —C 15 —F 16 -E 17 -R 18 —X 19 —X 20 —X 21 —X 22 —X 23 (SEQ ID NO:126) wherein R 1 is absent, CH 3 , C(O)CH 3 , C(O)CH 2 CH 3 , C(O)CH 2 CH 2 CH 3 , C(O)CH(CH 3 )CH 3 , C(O)CH 2 CH 2 CH 2 CH 3 , C(O)CH(CH 3 )CH 2 CH 3 , C(O)C 6 H 5 , C(O)CH 2 CH 2 (CH 2 CH 2 O) 1-5 Me, amido-2-PEG, or an N-acyl or N-alkyl amino protecting group, a lipid fatty acid group or a carbohydrate; R 2 is absent, OH, NH 2 , NH(CH 3 ), NHCH 2 CH 3 , NHCH 2 CH 2 CH 3 , NHCH(CH 3 )CH 3 , NHCH 2 CH 2 CH 2 CH 3 , NHCH(CH 3 )CH 2 CH 3 , NHC 6 H 5 , NHCH 2 CH 2 OCH 3 , NHOCH 3 , NHOCH 2 CH 3 , a carboxy protecting group, a lipid fatty acid group or a carbohydrate; X 14 is E or V; X 19 may be any hydrophobic amino acid residue, or D-isomer thereof; X 20 may be absent, or may be any neutral, hydrophobic or aromatic amino acid or D-isomer thereof; X 21 may be absent, or may be any positively charged residue or any aliphatic non-polar residue or D-isoform thereof; X 22 may be absent, or may be selected from the group consisting of G, V, L, I, P, S, T, W, F, E, Kac, or D-isomers thereof; X 23 may be absent, or is selected from the group consisting of G, A, I, L, Q, E, F, T, S, Y, and Kac and D-isomers thereof; and the peptide may be covalently linked to an antibody directly or via an intermediate linker connected to an N-terminus amino group or C-terminus carboxyl group of the peptide or the side chain of a linking residue selected from the group consisting of K, R, Y, C, T, S, homocysteine, homoserine, Dap, and Dab; where the linking residue is at one of residue positions 1, 2, 3, 4, 9, 10, 12, 14, 17 or the C-terminus residue; or a pharmaceutically acceptable salt thereof.